Correlation between XRCC1 Arg399Gln genetic polymorphisms and susceptibility to bladder cancer: a meta-analysis.

The relationship between XRCC1 polymorphisms and bladder cancer has been widely studied. Here, our meta-analysis was conducted to evaluate the correlations between common genetic polymorphisms in XRCC1 and susceptibility to bladder cancer. In order to derive a more precise estimation of the association, 27 clinical case-control studies (which met all the inclusion criteria) were included in this meta-analysis. A total of 8,539 cancer cases and 10,750 controls were involved in this meta-analysis. Overall, no significant association was detected in allelic model (A allele vs T allele odds ratio [OR] =0.87, 95% confidence interval [CI], 0.71-1.06), homozygote comparison (AA vs GG OR =1.12, 95% CI, 0.68-1.85), heterozygote comparison (AT vs TT OR =1.01, 95% CI, 0.81-1.26), dominant model (AA + AG vs GG OR =0.93, 95% CI, 0.85-1.02), and recessive model (AA vs AG + GG OR =1.01, 95% CI, 0.88-1.15), but a moderately significant association was found for AG vs GG (OR =0.241, 95% CI =0.17-0.35). Subgroup analysis based on ethnicity. Ethnicity analysis suggested that genetic polymorphisms in XRCC1 were not correlated with increased bladder cancer risk among Asians (all P>0.05). Therefore, we concluded that XRCC1 genetic polymorphism may not contribute to bladder cancer susceptibility in the present meta-analysis, and further well-designed studies with a large sample size are warranted to validate our conclusion.